Polio vaccines: hope, hype, and history repeating?

Fortner, Robert

doi:10.1136/bmj.p1763

Cited by 1 publication

(1 citation statement)

References 15 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…More than 800 million doses of nOPV2 have been used in 16 countries by late 2023, reducing the number of (reported) cVDPV2 cases from 689 in 2022 to 364 in 2023. Whether nOPV2 use will be sufficient to stop all cVDPV2 circulation is not yet known, as there is some evidence that nOPV2 can itself produce new vaccine-derived strains [ 20 ]. There has been a recent substantial increase in cVDPV1, which increases the need for regulatory approval of the nOPV1 vaccine with a low tendency to revert towards wild-type virulence.…”

Section: Practical Realities—currentmentioning

confidence: 99%

Population Immunity and Polio Eradication

Fine

2024

Pathogens

View full text Add to dashboard Cite

The Global Polio Eradication Initiative made immense progress after its establishment in 1988 as a consequence of high coverage with various poliovirus vaccines in all populations of the world. Problems have arisen in recent years, however, related to security issues in some countries, to the circulation of vaccine-derived polioviruses, and to the recognition that individuals with certain immune deficiencies can remain infected and infectious for many months or years. As natural infection and different vaccines have different effects on the immune system, the patterns of humoral and mucosal immunity to polioviruses in the world today are complex but are crucial to the ultimate success of the eradication initiative. This paper describes the background of the current situation and current immunological patterns and discusses their implications for managing population immunity to polioviruses in the years ahead.

show abstract

Section: Practical Realities—currentmentioning

confidence: 99%